A Differential Profile of Biomarkers between Patients with Atrial Fibrillation and Healthy Controls

Abstract

Atrial fibrillation (AF) is explained by anatomical and electrophysiological changes in the atria determined by high pressure, dilatation, infiltration and inflammation in the myocardium. There are some biomarkers implicated in these processes, namely, NT-proBNP, high sensitivity troponin (Hs-Tn), urate, galectin-3, ST2, C reactive protein and fibrinogen. The aim of this study was to assess differences in these biomarkers between patients with AF and healthy controls. We designed a cross-sectional study consecutively including all patients undergoing electrical cardioversion in our hospital for persistent AF and matched healthy controls. We included 115 patients with persistent non-valvular AF and 33 healthy subjects. The biomarkers NT-proBNP, ST2 and Hs-Tn T were significantly related to the presence of AF (1054 ± 833.30 vs. 58.31 ± 59.40, p < 0.001; 35.43 ± 15.89 vs. 27.43 ± 10.95, p < 0.001 and 10.25 ± 6.11 vs. 8.42 ± 6.85, p < 0.001, respectively). NT-proBNP was the best biomarker differentiating AF patients (area under the curve 0.995). The best NT-proBNP cut-off point to differentiate AF was 102 pg/mL; for Hs-Tn T it was 11.5 ng/L and for ST2 it was 37.7 ng/mL. It is possible that these biomarkers intervene at the onset of AF and have no role in AF maintenance.

Predictive value of soluble suppression of tumorigenicity 2 in atrial fibrillation: a systematic review and meta-analysis

“…After reading the full text, 14 studies were further excluded because 3 were reviews, 5 were irrelevant findings, and the other 6 were inadequate data. Finally, 24 studies ( 12 – 14 , 17 – 37 ) were included.…”

“…Table 1 displayed the baseline characteristics of 24 included studies from 2015 to 2022, comprising 14 prospective studies ( 14 , 17 – 23 , 26 , 29 – 31 , 33 , 37 ), 4 retrospective studies ( 24 , 25 , 27 , 32 ), 4 cross-sectional studies ( 12 , 13 , 34 , 35 ), and 2 case-control studies ( 28 , 36 ). Eleven studies were conducted in Asia (China, Thailand, Singapore), 10 studies in Europe (Germany, Poland, Finland, France, Norway, Spain, Sweden, Turkey), and 3 study in America (The united states).…”

“…sST2, mainly a well-known HF biomarker, and is also associated with worsening outcomes after myocardial infarction (MI) ( 10 , 11 ). Recent studies have identified the predictive value of sST2 in AF ( 12 – 14 ). However, these studies are small and contradictory.…”

A Cost-Effectiveness Analysis of Biomarkers for Risk Prediction in Atrial Fibrillation

“…Studies have demonstrated that abnormal biomarker concentrations reflecting cardiac and renal dysfunction as well as inflammation and oxidative stress identify patients at higher risk of developing AF. Merino-Merino et al [ 43 ], in a recent study comparing AF patients with healthy study participants, showed a relationship between NT-proBNP, ST2, high-sensitivity cardiac troponin T, and the presence of AF, with NT-proBNP showing the highest yield in differentiating patients with AF from healthy participants.…”

Metabolomics and Biomarkers for Paroxysmal and Persistent Atrial Fibrillation

“… 16 However, a comprehensive assessment of AF by combining several biomarkers has not been fully established. 17 Further, the differential metabolites (DMs) of different types of AF are not well established.…”